Rhea J. Longley

Rhea J. Longley

DPhil, Bachelor of Medical Research (First Class Honours)

Infectious Disease Specialist

Over 15 years of experience

Female📍 Melbourne

About of Rhea J. Longley

Rhea J. Longley is an Infectious Disease Specialist based in Melbourne, working out of Level 5, 792 Elizabeth St, Melbourne VIC 3000, Australia.


Her focus is on infections that can be tricky to diagnose or manage, including illnesses picked up from travel and infections that need careful treatment plans. In many cases, people come in with symptoms that just don’t add up, or they’ve already tried something and it hasn’t worked out. Over time, she helps patients sort through what’s going on, what needs urgent attention, and what can be followed up step by step.


Malaria is a key part of her work. That can include people who have been in malaria risk areas, as well as others who need advice on prevention, testing, and treatment. Malaria can feel severe quite quickly, and timing matters. She looks at the bigger picture and makes sure the plan fits the situation, not just the lab results.


With over 15 years of experience, she brings a calm, steady approach. Infectious disease care can be stressful for patients and families, especially when there’s uncertainty at first. She aims to keep things clear, explain the options in plain language, and stay practical about next steps.


Rhea’s education includes a DPhil in Clinical Medicine, Immunology, Parasitology, and Vaccinology from the University of Oxford (2013). She also completed a Bachelor of Medical Research (First Class Honours) in Biochemistry at the University of Tasmania (2009). That research background helps her understand infections in a deeper way, without making the conversation overly technical.


She has also been involved in academic work and publications, which supports her ongoing knowledge in infectious diseases and malaria. While the work is research-led, the clinic side stays patient-centred, and the emphasis stays on real-world decisions for care.


Clinical trial work isn’t a main part of the information available here. Still, her approach is evidence based and grounded in what’s known to work. If you’re dealing with an infection that needs a more focused infectious diseases review, she’s the kind of clinician who helps bring clarity when it’s needed most.

Education

  • DPhil in Clinical Medicine, Immunology, Parasitology, Vaccinology; University of Oxford; 2013
  • Bachelor of Medical Research (First Class Honours), Biochemistry; University of Tasmania; 2009

Services & Conditions Treated

Malaria

Publications

5 total
PTRAMP, CSS and Ripr form a conserved complex required for merozoite invasion of Plasmodium species into erythrocytes.

bioRxiv : the preprint server for biology • April 08, 2025

Benjamin Seager, Pailene Lim, Keng Lai, Lionel Feufack Donfack, Sheena Dass, Xiao Xiao, Nicolai Jung, Anju Abraham, Matthew Grigg, Nicholas Anstey, Timothy William, Jetsumon Sattabongkot, Andrew Leis, Rhea Longley, Manoj Duraisingh, Jean Popovici, Danny Wilson, Stephen Scally, Alan Cowman

Invasion of erythrocytes by members of the Plasmodium genus is an essential step of the parasite lifecycle, orchestrated by numerous host-parasite interactions. In P. falciparum Rh5, with PfCyRPA, PfRipr, PfCSS, and PfPTRAMP, forms the essential PCRCR complex which binds basigin on the erythrocyte surface. Rh5 is restricted to P. falciparum and its close relatives; however, PTRAMP, CSS and Ripr orthologs are present across the Plasmodium genus. We investigated PTRAMP, CSS and Ripr orthologs from three species to elucidate common features of the complex. Like P. falciparum, PTRAMP and CSS form a disulfide-linked heterodimer in both P. vivax and P. knowlesi with all three species forming a complex (PCR) with Ripr by binding its C-terminal region. Cross-reactive antibodies targeting the PCR complex differentially inhibit merozoite invasion. Cryo-EM visualization of the P. knowlesi PCR complex confirmed predicted models and revealed a core invasion scaffold in Plasmodium spp. with implications for vaccines targeting multiple species of malaria-causing parasites.

PTRAMP, CSS and Ripr form a conserved complex required for merozoite invasion of Plasmodium species into erythrocytes.

Research Square • May 09, 2025

Alan Cowman, Benjamin Seager, Pailene Lim, Keng-heng Lai, Lionel Feufack Donfack, Sheena Dass, Xiao Xiao, Nicolai Jung, Anju Abraham, Matthew Grigg, Nicholas Anstey, Timothy William, Jetsumon Sattabongkot, Andrew Leis, Rhea Longley, Manoj Duraisingh, Jean Popovici, Danny Wilson, Stephen Scally

Invasion of erythrocytes by members of the Plasmodium genus is an essential step of the parasite lifecycle, orchestrated by numerous host-parasite interactions. In P. falciparum Rh5, with PfCyRPA, PfRipr, PfCSS, and PfPTRAMP, forms the essential PCRCR complex which binds basigin on the erythrocyte surface. Rh5 is restricted to P. falciparum and its close relatives; however, PTRAMP, CSS and Ripr orthologs are present across the Plasmodium genus. We investigated PTRAMP, CSS and Ripr orthologs from three species to elucidate common features of the complex. Like P. falciparum, PTRAMP and CSS form a disulfide-linked heterodimer in both P. vivax and P. knowlesi with all three species forming a complex (PCR) with Ripr by binding its C-terminal region. Cross-reactive antibodies targeting the PCR complex differentially inhibit merozoite invasion. Cryo-EM visualization of the P. knowlesi PCR complex confirmed predicted models and revealed a core invasion scaffold in Plasmodium spp. with implications for vaccines targeting multiple species of malaria-causing parasites.

From pipettes to playdates: establishing a parent support group in a research setting.

Immunology And Cell Biology • February 17, 2025

Rhea Longley, Andre Samson, Georgia Atkin Smith, Alex Carey Hulyer, Trent Ashton, Nadia Davidson

In this article, we discuss our experiences and perspectives in forming a workplace Parents Group. We reflect on the need for these networks, what has worked well, and the challenges we've experienced. We also provide some practical advice for those with parenting-related career disruptions for addressing this topic in grant applications.

Applying novel Plasmodium Vivax serological exposure markers to quantify residual malaria transmission in the Philippines through repeated health facility surveys: the SMaRT study protocol.

BMC Infectious Diseases • February 12, 2025

Jhobert Bernal, Maria Macalinao, Katherine Cosca, Beaulah Boncayao, Ivo Mueller, Fe Esperanza Espino, Gillian Stresman, Jennifer Luchavez, Rhea Longley

Background: After decades of progress towards malaria elimination, Plasmodium vivax is now the predominant source of infection and the major obstacle towards elimination in the Asia-Pacific region. In the Philippines, the situation is slightly different with P. falciparum still accounting for the largest burden. However, there has been a steady increase in the total number of reported P. vivax cases in the main transmission hotspot of Palawan, as well as two years of consecutive outbreaks of P. vivax in the near-elimination setting of Sultan Kudarat. Here, we describe the protocol for a new study in Sultan Kudarat that aims to identify whether an underlying, hidden, burden of P. vivax contributes to the ongoing risk of outbreaks. Methods: A challenge for surveillance of P. vivax is the presence of an additional hidden liver-stage, where parasites (hypnozoites) lie dormant for weeks to months before causing a relapse of infection. Hypnozoites cannot be detected with commercial diagnostic tests. We have designed novel serological exposure markers of recent P. vivax infection, which indirectly inform on hypnozoite carriage. In this study we will conduct a prospective 18-month survey in health facilities within Kalamansig, Sultan Kudarat, and compare epidemiology and serological data with that in archival samples from Palawan. We will enroll both care-seeking individuals and their companions, and utilise remote geolocation to uncover spatial trends. Conclusions: This study will generate important data for the malaria control program in the Philippines whilst also demonstrating utility of P. vivax serological exposure markers in near-elimination settings. We will utilise this data to build a decision-making framework to support novel, evidence-based elimination strategies relevant for the Philippines and the wider Asia-Pacific region.

Stabilized designs of the malaria adhesin protein PvRBP2b for use as a potential diagnostic for Plasmodium vivax.

The Journal Of Biological Chemistry • January 11, 2025

Jaison D Sa, Lucas Krauss, Lauren Smith, Laura D'andrea, Li-jin Chan, Anju Abraham, Nicholas Kiernan Walker, Ramin Mazhari, Macie Lamont, Pailene Lim, Jetsumon Sattabongkot, Marcus Lacerda, Lyndes Wini, Ivo Mueller, Rhea Longley, Phillip Pymm, Sarel Fleishman, Wai-hong Tham

Plasmodium vivax is emerging as the most prevalent species causing malaria outside Africa. Most P. vivax infections are relapses due to the reactivation of the dormant liver stage parasites (hypnozoites). Hypnozoites are a major reservoir for transmission but undetectable by commercial diagnostic tests. Antibodies against P. vivax reticulocyte-binding protein 2b (PvRBP2b) are among the most reliable serological biomarkers for recent P. vivax infections in the prior 9 months and act as indirect biomarkers for risk of relapse. We sought to design stabilized variants of PvRBP2b, under stringent conditions of minimally perturbing the solvent-accessible surfaces to maintain its antigenicity profile. Furthermore, for some of the designs, due to limited diversity of natural PvRBP2b homologs, we combined AI-based ProteinMPNN and PROSS atomistic design calculations. The best, bearing 19 core mutations relative to PvRBP2b, expressed 16-fold greater amounts (up to 11 mg/l), and had 14 °C higher thermal tolerance than the parental protein. Critically, the stabilized designs retained binding to naturally acquired human mAbs with nanomolar affinities, suggesting that the immunologically competent surfaces were retained as was confirmed by crystallographic analyses. Using longitudinal observational cohorts from malaria endemic regions of Thailand, Brazil, and the Solomon Islands, we show that antibody responses against the designs are highly correlated with those against the parental protein and can classify individuals as recently infected with P. vivax. This efficient computational stability design methodology can be used to enhance the biophysical properties of other recalcitrant proteins for use as diagnostics or vaccine immunogens.

Frequently Asked Questions

What services do you offer?
I specialise in infectious diseases and provide assessment and treatment for conditions like malaria.
Do you treat malaria?
Yes. Malaria is one of the services I provide.
Where is your practice located?
Level 5, 792 Elizabeth Street, Melbourne, VIC 3000, Australia.
How many years of experience do you have?
I have over 15 years of experience in infectious disease medicine.
What qualifications do you hold?
I hold a DPhil in Clinical Medicine, Immunology, Parasitology and Vaccinology, and a Bachelor of Medical Research (First Class Honours). I studied at the University of Oxford and the University of Tasmania.
How do I book an appointment?
Please contact the clinic to arrange an appointment.

Contact Information

Level 5, 792 Elizabeth St, Melbourne, VIC 3000, Australia

Is this your profile?

Claim this profile →

Memberships

  • Australian Society for Immunology (ASI)
  • Victorian Infectious Diseases Service (VIDS)
  • International Union of Immunological Societies (IUIS)